glp-1 drugs uses Drug Overdose Glucagon-like peptide-1 - Wikipedia

The impetus to prescribe GLP-1 RAs primarily for obesity is continually growing

N Engl J Med 390(15):13941407 Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ et al (2024) Semaglutide and NT-proBNP in obesity-related HFpEF

However, this is less of an issue for well-known class-specific adverse effects

Emerging preclinical evidence suggests GLP-1 may influence neuronal survival, synaptic plasticity, and neuroinflammationprocesses that are disrupted in neurodegenerative conditions

It was marketed under the brand name Byetta and got approval in 2005

[DOI] [PubMed] [Google Scholar] 31.Husain M., Birkenfeld A.L., Donsmark M., Dungan K., Eliaschewitz F.G., Franco D.R., Jeppesen O.K., Lingvay I., Mosenzon O., Pedersen S.D., et al